title: Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma.
abstract: In 1977, a program of early, wide-field radiation therapy (RT) to the central nervous system and repeated lumbar intrathecal (IT) medications along with systemic chemotherapy was begun by the Intergroup Rhabdomyosarcoma Study (IRS) for patients younger than 21 years of age with cranial parameningeal sarcoma and a high risk of meningeal extension. From 1977 until 1987, 149 eligible patients with high-risk cranial parameningeal sarcoma were enrolled in IRS trials. None had evidence of lower extremity or sphincter impairment at diagnosis. Five of the 149 (3.4%) had ascending myelitis at 5.5 to 9 months after the initiation of therapy, with loss of sphincter control and inability to walk; this progressed to severe flaccid quadriparesis and necessitated long-term ventilatory support in 4. All five had received vincristine, dactinomycin, cyclophosphamide, and doxorubicin; four also had received cisplatin and three also had received etoposide. All patients received 4770 to 5500 cGy to the primary tumor, and four patients received 3000 cGy of cranial RT. Three patients received cervical RT and two received spinal RT. The patients also received four to seven courses of IT methotrexate, hydrocortisone, and cytosine arabinoside. Three patients died: one after local tumor recurrence with central nervous system extension and two without known recurrence. In one of the latter patients, the results of an autopsy showed necrosis of the cervical spinal cord and caudal medulla. Although the exact cause of this complication is unclear, no additional cases have been reported to the IRS since the protocol was revised in 1987 to reduce the doses of the IT drugs and to limit them to four courses each.
authors.affiliation: University of Texas M.D. Anderson Cancer Center, Division of Pediatrics, Houston 77030.
authors.forename: B
authors.initials: B
authors.lastname: Raney
authors.forename: M
authors.initials: M
authors.lastname: Tefft
authors.forename: R
authors.initials: R
authors.lastname: Heyn
authors.forename: W
authors.initials: W
authors.lastname: Newton
authors.forename: P M
authors.initials: PM
authors.lastname: Jones
authors.forename: V
authors.initials: V
authors.lastname: Haeberlen
authors.forename: H
authors.initials: H
authors.lastname: Maurer
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D007278:Injections, Spinal; D008297:Male; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009187:Myelitis / Q000209:etiology*; D009361:Neoplasm Invasiveness; D011879:Radiotherapy Dosage; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000532:radiotherapy; D012509:Sarcoma / Q000188:drug therapy* / Q000532:radiotherapy*; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000532:radiotherapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000532:radiotherapy